Log In Sign up
The largest database of trusted experimental protocols

Tim3 clone rmt3 23

Manufactured by Thermo Fisher Scientific
Visit Supplier

The TIM3 (clone RMT3-23) is a lab equipment product offered by Thermo Fisher Scientific. It is a monoclonal antibody designed to detect the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) protein, which plays a role in regulating immune responses. The core function of this product is to enable the detection and study of TIM-3 in various research applications.

Automatically generated - may contain errors

Lab products found in correlation

Foxp3 clone fjk 16s, by Thermo Fisher Scientific (3 mentions) Pd l1, by BioLegend (2 mentions) Ctla 4 clone uc10 4b9, by Thermo Fisher Scientific (2 mentions) Cd45 clone 30 f11, by BioLegend (2 mentions) Cd11b, by BioLegend (2 mentions) Cd206, by BioLegend (2 mentions) Cd62l, by BioLegend (2 mentions) Cd103, by BioLegend (2 mentions) Live dead aqua, by Thermo Fisher Scientific (1 mentions) Pd 1 clone j43, by Thermo Fisher Scientific (1 mentions) Cd3 clone 145 2c11, by Thermo Fisher Scientific (1 mentions) Cd19 clone 1d3, by BD (1 mentions) Cd8 clone 53 6, by BD (1 mentions) Magnetic bead, by Miltenyi Biotec (1 mentions) Clone 30 f11, by BioLegend (1 mentions) Clone hit3a, by BioLegend (1 mentions) Pd 1 clone eh12.2h7, by BioLegend (1 mentions) Ifnγ clone xmg1, by BioLegend (1 mentions) Cd3 clone 17a2, by BioLegend (1 mentions) Il 2 clone jes6 5h4, by BioLegend (1 mentions)

4 protocols using tim3 clone rmt3 23

1

Immune Profiling of Lung Infiltrates

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isolated lung infiltrating immune cells were stained with fluorescently labeled anti-mouse antibody CD45 (clone 30-F11, BioLegend), CD3 (clone 17A2, BioLegend), CD49b (clone DX5, BioLegend), CD19 (clone 6D5, BioLegend), CTLA-4 (clone UC10-4B9, Invitrogen), CD69 (clone H1.2F3, BioLegend), TIM3 (clone RMT3-23, Invitrogen), FOXP3 (clone FJK-16s, eBioscience), PD-1 (clone 29F.1A12, BioLegend), KI-67 (clone 16A8, BioLegend), CD4 (clone GK1.5, BioLegend), CD8 (clone 53-6.7, BioLegend), H-2 (clone M1/42, BioLegend), Ly6G (clone 1A8, BioLegend), CD103 (clone 2E7, BioLegend), F4/80 (clone BM8, BioLegend), CD86 (clone GL-1, BioLegend), PD-L1 (clone 10F.9G2, BioLegend), Ly6C (clone HK1.4, BioLegend), CD206 (clone C068C2, BioLegend), CD11B (clone M1/70, BioLegend), CD11C (clone N418, BioLegend), CD4 (clone RM4-4, BioLegend), CD8 (clone 53-6.7, BioLegend), GZMB (clone GB11, BD Horizon), CD62L (clone MEL-14, BioLegend), and CD44 (clone IM7, BioLegend).
Han H., Li S., Chen T., Fitzgerald M., Liu S., Peng C., Tang K.H., Cao S., Chouitar J., Wu J., Peng D., Deng J., Gao Z., Baker T.E., Li F., Zhang H., Pan Y., Ding H., Hu H., Pyon V., Thakurdin C., Papadopoulos E., Tang S., Gonzalvez F., Chen H., Rivera V.M., Brake R., Vincent S, & Wong K.K. (2021). Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Research, 81(20), 5311-5324.
+ Open protocol
+ Expand
2

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isolated lung infiltrating immune cells were stained with fluorescently labeled anti-mouse antibody CD45 (clone 30-F11, BioLegend), CD3 (clone 17A2, BioLegend), CD49b (clone DX5, BioLegend), CD19 (clone 6D5, BioLegend), CTLA-4 (clone UC10-4B9, Invitrogen), CD69 (clone H1.2F3, BioLegend), TIM3 (clone RMT3-23, Invitrogen), FOXP3 (clone FJK-16s, eBioscience), PD-1 (clone 29F.1A12, BioLegend), KI-67 (clone 16A8, BioLegend), CD4 (clone GK1.5, BioLegend), CD8 (clone 53-6.7, BioLegend), H-2 (clone M1/42, BioLegend), Ly6G (clone 1A8, BioLegend), CD103 (clone 2E7, BioLegend), F4/80 (clone BM8, BioLegend), CD86 (clone GL-1, BioLegend), PD-L1 (clone 10F.9G2, BioLegend), Ly6C (clone HK1.4, BioLegend), CD206 (clone C068C2, BioLegend), CD11B (clone M1/70, BioLegend), CD11C (clone N418, BioLegend), CD4 (clone RM4-4, BioLegend), CD8 (clone 53-6.7, BioLegend), GZMB (clone GB11, BD Horizon), CD62 L (clone MEL-14, BioLegend), and CD44 (clone IM7, BioLegend).
Han H., Li S., Chen T., Fitzgerald M., Liu S., Peng C., Tang K.H., Cao S., Chouitar J., Wu J., Peng D., Deng J., Gao Z., Baker T.E., Li F., Zhang H., Pan Y., Ding H., Hu H., Pyon V., Thakurdin C., Papadopoulos E., Tang S., Gonzalvez F., Chen H., Rivera V.M., Brake R., Vincent S, & Wong K.K. (2021). Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Research, 81(20), 5311-5324.
+ Open protocol
+ Expand
3

Isolation and Characterization of Tumor-Infiltrating Lymphocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
In order to obtain tumor infiltrating lymphocytes, tumors from third passage B6CaP cells grown in parallel were mechanically disintegrated and digested for 1 h at 37°C in RPMI media with 10 mg/ml of Collagenase IV and 1 mg/ml of DNase. After digestion, white blood cells were isolated from tumors using anti CD45 antibodies conjugated with magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s protocol. Tumor infiltrating leukocytes were characterized with antibodies against CD3 (clone 145-2C11, eBioscience), CD19 (clone 1D3, BD Biosciences), CD49b (clone DX5, BD Biosciences), CD4 (clone H129.19, BD Biosciences), CD8 (clone 53-6.7, BD Biosciences), PD-1 (clone J43, eBioscience), Tim-3 (clone RMT3-23, eBioscience), Lag-3 (clone C9B7W, eBioscience) and CTLA4 (clone UC10-4F10-11, BD Biosciences). Flow through cells not captured by bead selection were stained with PDL-1 antibody (clone MIH5, eBioscience). For viability staining we used Live/Dead Aqua (Life Technologies). Gating controls were prepared with Fluorescence Minus One (FMO) stains of splenocytes or isotype control for tumor cells. Data were analyzed with FlowJo software (TreestarInc, Ashland, OR, USA).
Simons B.W., Kothari V., Benzon B., Ghabili K., Hughes R., Zarif J.C., Ross A.E., Hurley P.J, & Schaeffer E.M. (2019). A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host. Oncotarget, 10(64), 6845-6854.
+ Open protocol
+ Expand
4

Immunophenotyping of Lung Infiltrating Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lung infiltrating immune cells were stained with different combinations of fluorochrome-coupled antibodies against mouse CD45 (clone 30-F11, Biolegend), CD3 (clone 17A2, Biolegend), CD4 (clone GK1.5, Biolegend), CD8 (clone 53-6.7, Biolegend), CD11b (clone M1/70, Biolegend), CD11c (clone N418, Biolegend), Foxp3 (clone FJK-16s, eBioscience), CD279 (PD-1, clone 29F.1A12, Biolegend), CD152 (CTLA-4, clone UC10-4B9, eBioscience), Tim-3 (clone RMT3–23, eBioscience), CD223 (Lag-3, clone C9B7W, Biolegend), IL-2 (clone JES6-5H4, Biolegend), IFNγ (clone XMG1.2, Biolegend), BrdU (clone Bu20a, Biolegend). Jurkat, PD-1-Jurkat, and human PBMCs were stained with fluorochrome-coupled antibodies against human CD3 (clone HIT3a, Biolegend), CD4 (clone OKT4, Biolegend), and CD279 (PD-1, clone EH12.2H7, Biolegend).
Deng J., Wang E.S., Jenkins R.W., Li S., Dries R., Yates K., Chhabra S., Huang W., Liu H., Aref A.R., Ivanova E., Paweletz C.P., Bowden M., Zhou C.W., Herter-Sprie G.S., Sorrentino J.A., Bisi J.E., Lizotte P.H., Merlino A.A., Quinn M.M., Bufe L.E., Yang A., Zhang Y., Zhang H., Gao P., Chen T., Cavanaugh M.E., Rode A.J., Haines E., Roberts P.J., Strum J.C., Richards W.G., Lorch J.H., Parangi S., Gunda V., Boland G.M., Bueno R., Palakurthi S., Freeman G.J., Ritz J., Haining W.N., Sharpless N.E., Arthanari H., Shapiro G.I., Barbie D.A., Gray N.S, & Wong K.K. (2017). CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation. Cancer discovery, 8(2), 216-233.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!